Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards

Diseasesort ascending Cell Type Therapeutic or Technology Institution Stage Project Objective Details
Leukemia, Acute Myeloid (AML) Cancer Stem Cell Antibody Immune-Onc Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
Kidney Failure Adult Stem Cell Donor cell therapy Stanford
Clinical Trial, Phase 1 or Phase 1/2
Kidney Failure Adult Stem Cell Donor cell therapy Medeor Therapeutics
Clinical Trial, Phase 3
Kidney Failure Adult Stem Cell Donor cell therapy Stanford
Clinical Trial, Phase 1 or Phase 1/2
IPEX Syndrome,
Immune Disease
Vital Research Opportunity Gene Therapy, cell free Stanford
IND
IPEX Syndrome Adult Stem Cell Gene-modified, personalized cell therapy ImmunoVec
Pre-IND/IDE or Equivalent
Intestinal Disease,
Neurological Disorders
iPS Cell Donor cell therapy CHLA
Pre-IND/IDE or Equivalent
Inflammatory bowel disease Adult Stem Cell Donor cell therapy Vitabolus, Inc.
Development Candidate, Proof of Concept
Immune Disease,
Severe Combined Immunodeficiency, X-linked (X-SCID)
Adult Stem Cell Gene-modified, personalized cell therapy St. Jude
Clinical Trial, Phase 1 or Phase 1/2
Immune Disease,
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
Adult Stem Cell Gene-modified, personalized cell therapy Orchard Therapeutics
Clinical Trial, Phase 2
Immune Disease,
Leukocyte Adhesion Deficiency
Adult Stem Cell Gene-modified, personalized cell therapy Rocket Pharmaceuticals, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Immune Disease,
X-linked Chronic Granulomatous Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
Hyper IgM Syndrome,
Immune Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Pre-IND/IDE or Equivalent
Huntington's Disease Embryonic Stem Cell Donor cell therapy UC Irvine
IND
HIV/AIDS Personalized cell therapy COH
IND
HIV/AIDS,
Immune Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS Adult Stem Cell Gene-modified, personalized cell therapy COH
Clinical Trial, Phase 1 or Phase 1/2
HIV-related Lymphoma,
HIV/AIDS
Adult Stem Cell Gene-modified, personalized cell therapy UC Davis
Clinical Trial, Phase 1 or Phase 1/2
Hemophilia A Adult Stem Cell Gene modification COH
Development Candidate, Proof of Concept
Heart failure Embryonic Stem Cell Donor cell therapy Stanford
Clinical Trial, Phase 1 or Phase 1/2
Heart failure iPS Cell Exosomes based therapy Stanford
Development Candidate, Proof of Concept
Epidermolysis Bullosa iPS Cell Gene-modified, personalized cell therapy Stanford
Development Candidate, Proof of Concept
Epidermolysis Bullosa iPS Cell Gene-modified, personalized cell therapy Stanford
Pre-IND/IDE or Equivalent
Duchenne Muscular Dystrophy Somatic Cell Gene Therapy, cell free MyoGene Bio LLC
Pre-IND/IDE or Equivalent
Dementia iPS Cell Donor cell therapy Gladstone
Development Candidate, Proof of Concept
Cystinosis,
Kidney Failure
Adult Stem Cell Gene-modified, personalized cell therapy UCSD
Clinical Trial, Phase 1 or Phase 1/2
COVID-19 Adult Stem Cell Vaccine UCLA
Development Candidate, Proof of Concept
COVID-19 Adult Stem Cell Small molecule therapy UCLA
Pre-IND/IDE or Equivalent
COVID-19,
Respiratory Disorders
Adult Stem Cell Donor cell therapy Celularity Inc
Clinical Trial, Phase 1 or Phase 1/2
COVID-19 iPS Cell Small molecule therapy UCSD
Development Candidate, Proof of Concept
COVID-19,
Respiratory Disorders
iPS Cell Small molecule therapy Sanford-Burnham
Development Candidate, Proof of Concept
COVID-19 Embryonic Stem Cell,
iPS Cell
Gene-modified, donor cell therapy COH
Proof of Concept
COVID-19 Adult Stem Cell Gene-modified, donor cell therapy UCLA
Development Candidate, Proof of Concept
COVID-19 iPS Cell Model system development UC Berkeley
Proof of Concept
COVID-19,
Respiratory Disorders
iPS Cell Small molecule therapy UCLA
Development Candidate, Proof of Concept
COVID-19,
Respiratory Disorders
Other,
Vital Research Opportunity
Convalescent Plasma COH
Research Insights
COVID-19 Adult Stem Cell Donor cell therapy UCSF
Clinical Trial, Phase 2
Corneal Damage Adult Stem Cell Personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
Cartilage defect Embryonic Stem Cell Donor cell therapy USC
IND
Heart Disease iPS Cell Donor cell therapy UC Davis
Development Candidate, Proof of Concept
Heart Disease Adult Stem Cell Antibody UCLA
Pre-IND/IDE or Equivalent
Heart Disease iPS Cell Protein/peptide therapy Regencor, Inc.
Pre-IND/IDE or Equivalent
Heart Disease iPS Cell Model system development Organos Inc.
Tool/Resources/Bottleneck
Heart Disease iPS Cell Model system development Stanford
Development Candidate, Proof of Concept
Heart Disease,
Danon Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCSD
Development Candidate, Proof of Concept
Canavan Disease iPS Cell Gene-modified, personalized cell therapy COH
Pre-IND/IDE or Equivalent
Brain Injury, hypoxic, ischemic Adult Stem Cell Donor cell therapy Sanford-Burnham
Pre-IND/IDE or Equivalent
Brain Cancer,
Neurological Disorders
Embryonic Stem Cell Exosomes based therapy UC Irvine
Development Candidate, Proof of Concept
Brain Cancer Somatic Cell Gene-modified, personalized cell therapy UCSF
Pre-IND/IDE or Equivalent
Brain Cancer Adult Stem Cell Gene-modified, personalized cell therapy COH
Clinical Trial, Phase 1 or Phase 1/2

Pages

Icon for csv export